Kornimate/medical-research-clean huggingface dataset:
study of blood and tissue samples from patients receiving androgen deprivation for newly diagnosed prostate cancer

Conditions: Prostate Cancer

Summary: rationale: studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research study is looking at blood and tissue samples from patients with prostate cancer receiving androgen deprivation therapy.

objectives: * to identify the molecular and pathophysiological changes which occur during the early stages of androgen deprivation (ad) and during emerging castration-resistant prostate cancer. * to test functional imaging as a non-invasive tool to measure treatment response and validate this using biological endpoints. * to develop clinical models to predict how tumors will respond to ad and identify new targets once ad fails. outline: * group a: patients likely to receive androgen deprivation (ad) as first-line therapy undergo blood and prostate biopsy sample collection before and after treatment on days 0 and 14 or 90. patients receive an androgen receptor inhibitor followed by maintenance with a gonadotropin-releasing hormone analogue beginning on day 0. patients also undergo diffusion-weighted mri, mr spectroscopic imagining, quantitative t1w mapping, and t1w perfusion sequence. * group b: patients already receiving ad undergo blood and prostate biopsy sample collection within 4 weeks of diagnosis of castration-resistant prostate cancer and before initiating any second-line therapy. blood and tissue samples are assessed via dna and rna genetic analysis, gene expression studies, and comparative genomic hybridization to identify novel markers of androgen response and resistance. peer reviewed and funded or endorsed by cancer research uk.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * high clinical suspicion of prostate cancer, based on an abnormal digital rectal examination and psa (\> 20 ng/ml) * newly diagnosed, castration-resistant prostate cancer * clinical stage ≥ t2c disease * significant tumor volume on initial diagnostic biopsy (\> 50% of cores) * likely to receive androgen deprivation therapy for prostate cancer patient characteristics: * no contraindication to transrectal needle biopsy * no contraindication to mri or prostate needle biopsy prior concurrent therapy: * see disease characteristics

Keywords: stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer
novel porcine dermal matrix in the treatment of multiple adjacent gingival recessions

Conditions: Recession, Gingival

Summary: the aim of this study was to assess the clinical efficacy of the acellular porcine derived collagen matrix (padm) in comparison with connective tissue graft (sctg ) in the treatment of multiple adjacent gingival recessions (magr). the primary objectives of the study were to evaluate mean and complete roots coverage. additionally, the secondary objective was to evaluate and compare the clinical effectiveness of padm and sctg for the treatment of magr defects applying modified coronally advanced tunnel technique (mcat).

treatment of multiple adjacent gingival recessions (magr) still presents a challenge for the clinician. the management of soft tissues becomes more complicated and the wound healing may be compromised by a variety of factors. according to the available medical databases, predictable root coverage is possible for multiple-tooth recession defects using subepithelial connective tissue graft (sctg) procedures. however, alternative materials to sctg are supported by evidence of varying strength, with the need for additional research to confirm their performance and success rate. because of that, the aim of this study was to assess the clinical efficacy of the acellular porcine derived collagen matrix (padm) in comparison with connective tissue graft (sctg ) in the treatment of multiple adjacent gingival recessions (magr). this study is a randomised controlled clinical trial of 12 months duration. sixteen patients with a total of 81 magr miller's class i or ii were enrolled in this study. recessions were randomly treated with padm and sctg, combined with a modified coronally advanced tunnel technique (mcat). several parameters, such as gingival recession coverage (rc), keratinized tissue width (ktw), keratinized tissue thickness (ktt) and clinical attachment level (cal) were recorded at baseline and one year postoperatively. healing index (hi) was registered on 1st, 2nd, and 3rd-week post-surgery in order to estimate healing events.

Eligibility criteria:
inclusion criteria: 1. at least two multiple maxillaries or mandibular miller's class i and ii recession, more than \>2mm defects together with similar contralateral lesions 2. no active periodontal disease with pd\>4mm 3. absence of the radiographic signs of periapical infection on the teeth to be treated or on the adjacent teeth 4. a full mouth plaque index \<20% and gingival index \< 1 exclusion criteria: 1. the inflammatory periodontal disease/ untreated periodontal conditions 2. previous surgical attempt to correct gingival recession 3. pregnant or breastfeeding women 4. systemic diseases with compromised healing potential or infectious diseases

Keywords: multiple gingival recessions collagen matrix connective tissue graft tunnel technique
effects of chromium picolinate on food intake

Conditions: Obesity; Atypical Depression

Summary: the purpose of this study is to test the effects of chromium picolinate on food intake, food cravings, eating attitudes, and appetite. if chromium picolinate is found to have a beneficial impact on satiety and food intake, then this supplement may be an alternative or adjunctive treatment for overweight people desiring to modify their food intake. the primary hypothesis of this study is that among individuals who report being carbohydrate cravers, chromium picolinate supplementation will reduce food intake during a test lunch meal and produce greater satiety in comparison to a placebo.


Eligibility criteria:
inclusion criteria: inclusion criteria are: 1. healthy female who has not been diagnosed with diabetes, cardiovascular illness, or other chronic diseases, 2. food craver, determined by self-reported craving for carbohydrates on two out of three validated measures of food cravings, 3. \> 18 years of age and \< 50 years of age, and 4. body mass index between 25 and 39.9 kg/m2. participants will be scheduled for testing during the luteal phase of their menstrual cycle to limit the confounding effect of the menstrual cycle on energy intake. we will include women who are taking monophasic oral contraceptives but will exclude other oral contraceptive regimens. participants with very irregular menstrual cycles will also be excluded because this irregularity will make it very difficult to schedule testing during the luteal phase of the menstrual cycle. exclusion criteria: potential participants will be excluded for the following reasons: 1. participants who report smoking cigarettes will be excluded because of the effects of nicotine upon taste and appetite, 2. participants who have a diagnosable eating disorder (i.e., anorexia or bulimia nervosa) will also be excluded since intentional restriction of eating and binge eating/overeating could increase the variability of the data, 3. participants who report using diet pills will be excluded since diet pills may potentially influence appetite, hunger, and/or satiety, 4. participants will be excluded if they are taking anti-depressant medications, anti-psychotic medications, or any medications that may potentially influence appetite, hunger, and/or satiety, 5. participants who are not determined to be carbohydrate cravers will be excluded, 6. participants will also be excluded if they report any allergies to the foods that will be used in the study.
effects of fixation technique on thoracic epidural catheter displacement

Conditions: Thoracic Epidural

Summary: the purpose of our study is to assess the effectiveness of dermabond as a thoracic epidural fixation technique compared to both mastisol and the grip-lok fixation bandage, two common, widely used techniques for epidural fixation.


Eligibility criteria:
inclusion criteria: * surgical patient * receiving a thoracic epidural * 18 years of age or older exclusion criteria: * patient refusal * allergy to adhesives or local anesthesia * pregnancy * contraindication to receiving an epidural including coagulopathy, infection, elevated icp, or severe pre-existing neurologic disorders
usefulness of metoclopramide to improve endoscopic visualization in upper gastrointestinal bleeding

Conditions: Upper Gastrointestinal Bleeding

Summary: a prospective, randomized, double-blind study will be conducted, including all patients with upper gastrointestinal bleeding, defined as vomiting blood or black bowel movements, within 24 hours prior to admission. patients will be randomized to receive intravenous metoclopramide 20 mg or placebo, a placebo is a look-alike substance that contains no active drug. then endoscopy will be performed in the following 120 minutes, evaluating endoscopic visualization with the modified avgerinos scale.

a prospective, longitudinal, randomized, double-blind study will be carried out in which all patients who come to the university hospital "dr. josé eleuterio gonzález" with upper gastrointestinal tract bleeding, defined in our study as hematemesis or melena, including patients with this condition in the 24 hours prior to admission. patients will be randomized to receive metoclopramide 20 mg iv or placebo, this randomization will be performed by means of a computer sequence to receive each of the treatment sequences. subsequently, the upper endoscopy will be performed in the following 120 minutes, and the endoscopic visualization will be evaluated by the physician performing the procedure by means of the modified avgerinos scale; which gives a score of 0-2 according to the percentage of mucosal vision; 0= \ 75% visible surface, evaluating fundus, body, antrum and bulb, a score ≥ 6 will be considered a clean stomach and a score ≤ 5 will be considered full stomach. the diagnosis of origin of the upper gastrointestinal tract bleeding will be determined by the physician in charge of performing the endoscopy. all cases will be filmed and another physician will review the cases and validate the avgerinos score, as well as the final diagnosis reported.

Eligibility criteria:
inclusion criteria: * hospitalized patients ≥18 years of age with variceal and non-variceal upper gastrointestinal tract bleeding (hematemesis and/or melena). * ≤12 hours of bleeding evolution. * hemodynamic stability at the time of upper endoscopy. exclusion criteria: * patients \<18 years old. * pregnant patients. * metoclopramide allergy. * refusal to be part of the study protocol.

Keywords: metoclopramide endoscopy hematemesis melena
preemptive paracetamol for postoperative pain

Conditions: Pain; Surgical Wound

Summary: the purpose of this study is to test whether a dose of paracetamol given before surgical incision is more effective at reducing postoperative pain and analgesic consumption in cervical spine surgery versus a dose given at the end of surgery.


Eligibility criteria:
inclusion criteria: * aged 18-80 years old * patients listed for non-malignant cervical spinal surgery * general anaesthesia * capacity to give informed consent * ability to use pca device and pain score scale * asa i, ii and iii * \>50kg in weight exclusion criteria: * allergy or sensitivity to paracetamol, proparacetamol or morphine * liver disease * renal disease (creatinine clearance \<30ml/min) * bleeding disorder * chronic alcoholism * chronic malnutrition * dehydration * g6pd deficiency * hypernatraemia (na \>150) * hypokalaemia (k \<3.5) and hyperchloraemia * pregnancy or breast-feeding
study of romosozumab (amg 785) administered to healthy participants and patients with stage 4 renal impairment or stage 5 renal impairment requiring hemodialysis

Conditions: Osteoporosis

Summary: the purpose of this study is to evaluate the safety, tolerability, and immunogenicity profile of romosozumab after a single 210 mg subcutaneous dose in healthy participants and patients with stage 4 renal impairment (ri) or stage 5 ri requiring hemodialysis.


Eligibility criteria:
inclusion criteria - all subjects : * males or females ≥ 50 years of age * body weight ≥ 45 and ≤ 110 kg * willing to adhere to calcium and vitamin d supplementation requirements * females must be of non-reproductive potential inclusion criteria - subjects with renal impairment (groups 1 and 2): * group 1 - stage 4 ri (estimated glomerular filtration rate (egfr) 15-29 ml/min/1.73 m²) * group 2 - end stage renal disease requiring hemodialysis inclusion criteria - healthy subjects (group 3): • renal function defined as an estimated glomerular filtration rate (egfr) ≥ 80 ml/min/1.73 m² exclusion criteria - all subjects: * history of metabolic or bone disease (except for metabolic bone disease in renal impairment (ri) subjects) * history of osteoporosis, vertebral fracture, or fragility fracture of the wrist, humerus, hip, or pelvis after age 50 * recent bone fracture * vitamin d insufficiency * hypocalcemia or hypercalcemia * hypomagnesemia * hypophosphatemia * untreated hyper- or hypothyroidism * females with a positive pregnancy test * males with pregnant partners * females who are lactating/breastfeeding or plan to breastfeed on study and for 3 months after receiving the dose of study drug * history of spinal stenosis * history of facial nerve paralysis * positive for human immunodeficiency virus (hiv) antibodies * positive for hepatitis b surface antigen or detectable hepatitis c * malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical, or breast ductal carcinoma in situ) within 5 years before screening * history of solid organ or bone marrow transplants exclusion criteria - healthy subjects (group 3) * current hyper- or hypoparathyroidism

Keywords: osteoporosis, bone, renal, insufficiency, kidney, hemodialysis, impairment
yasu research registry: for young adults with cancer

Conditions: Cancer; Leukemia; Sarcoma; Germ Cell Cancer; Lymphoma; Colorectal Cancer; Melanoma; Breast Cancer

Summary: the goal of this observational research registry is to learn about health, wellbeing, and needs of survivors of young adult cancer (diagnosed between the ages of 18 and 39). the main question\[s\] it aims to understand are: * what are the levels of depression, anxiety, social support, and financial distress * determine effectiveness of yasu programming by measuring changes over time with this registry, the investigators also plan to identify survivors who may be eligible for participation in future research studies pertaining to young adult cancer. participants will be asked to complete electronic surveys every 6 to 12 months during participation in the registry.

the study will be conducted online.

Eligibility criteria:
inclusion criteria: 1. cancer diagnosis received between the ages of 18 and 39. 2. able to speak and read english exclusion criteria: 1. inability to provide consent (such as neurological illness or mental incapacity) 2. has not registered as a member of yasu

Keywords: young adult cancer
clinical characteristics of metabolic associated fatty liver disease

Conditions: Metabolic Associated Fatty Liver Disease; Clinical Features

Summary: metabolic associated fatty liver disease (mafld), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society. with the improvement of living standards and changes in dietary habits, mafld patients show a younger and increasing trend, but there is still no specific drug. the clinical features and prognosis of mafld may be different with different metabolic disorder phenotypes and treatment measures. therefore, further systematic study of the clinical characteristics and prognosis of mafld patients will be of great significance for the formulation of corresponding clinical prevention and treatment strategies.

metabolic associated fatty liver disease (mafld), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society. with the improvement of living standards and changes in dietary habits, mafld patients show a younger and increasing trend, but there is still no specific drug. the clinical features and prognosis of mafld may be different with different metabolic disorder phenotypes and treatment measures. therefore, further systematic study of the clinical characteristics and prognosis of mafld patients will be of great significance for the formulation of corresponding clinical prevention and treatment strategies.

Eligibility criteria:
inclusion criteria: 1. 18 years or older; 2. mafld patients exclusion criteria: 1. malignant tumors; 2. mental illness, severe impairment of cardiopulmonary function, severe renal insufficiency, severe infections, and cerebrovascular accidents; 3. received liver or other organ transplants.

Keywords: metabolic associated fatty liver disease clinical features
a study of the rules for insulin dosing in patients using multiple daily injections

Conditions: Diabetes Mellitus Type 1

Summary: this study will be conducted in subjects with type 1 diabetes mellitus on multiple daily insulin injections to determine the correct insulin dosing formulas. subjects will be evaluated using continuous glucose monitoring.

subjects with stable type 1 diabetes mellitus on multiple daily insulin injections including basal and bolus will be selected in order to determine the correct insulin dosing formulas. subjects will be placed on continuous glucose sensor (cgms) and an isocaloric diet. subjects will have the cgms downloaded daily and the insulin doses adjusted if necessary. subject will do four smbgs daily to calibrate cgms and on last day a 7-point smbg. subjects will be on lispro and glargine insulin. basal insulin will be once a day.

Eligibility criteria:
inclusion criteria: * age: \>17 years * type 1 diabetes * diabetes duration \> 3 months * on treatment with multiple daily injections either one or more basal insulin injections each day for 6 weeks * hba1c \<9.0% * stable hba1c in the proceeding 3 months (i.e., change \<1%) * demonstrated adherence to visits and instructions * attend a class in meal carbohydrate content estimation or have demonstrated knowledge of carbohydrate counting exclusion criteria: * major stress event during or for 6 weeks before the evaluation * taking a medication that can alter insulin sensitivity * within one week of menses * unstable eating or activity pattern * pregnancy * weight gain of \> 1.5 kg during the preceding 3 months * serum creatinine of \>1.5 mg/dl * active liver disease * evidence of autonomic neuropathy, especially gastroparesis * any antidiabetic medication other than insulin * treatment with continuous subcutaneous insulin infusion

Keywords: diabetes mellitus type 1 continuous glucose monitoring
a ddi study to investigate pk and safety of cefiderocol in combination with xeruborbactam in healthy adult participants

Conditions: Bacterial Infections

Summary: a phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants

qpex biopharma, inc. is developing xeruborbactam, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases in combination with a beta-lactam antibiotic. cefiderocol is a cephalosporin antibiotic approved in the us for the treatment of complicated urinary tract infections including pyelonephritis, and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Eligibility criteria:
inclusion criteria: * male or female, 18 to 55 years of age (inclusive) at the time of signing the informed consent. * body mass index (bmi) ≥ 18.5 and 32 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive) * subjects must be judged to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram and laboratory profile * voluntary consent to participate in the study. exclusion criteria: * history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease. * a subject with active drug or alcohol abuse within 2 years prior to the initial study drug administration * females who are pregnant or lactating * documented hypersensitivity reaction or anaphylaxis to any medication. history of any severe hypersensitivity, anaphylaxis, or allergic reaction to cefiderocol or any other beta-lactam antibacterial drugs, or any other excipients used in the formulation (eg, cephalosporins, penicillins, carbapenems, or monobactams)

Keywords: beta-lactamase inhibitor